Business Context and Reporting Period
This Form 8-K, dated March 7, 2019, reports a material definitive agreement entered into by Stellar Biotechnologies, Inc. (the "Registrant") with Edesa Biotech Inc., a privately-held Canadian company focused on dermatological and gastrointestinal therapeutics. The filing announces a proposed share exchange transaction where Stellar will acquire all issued share capital of Edesa, making Edesa a wholly-owned subsidiary. Upon closing, Stellar will change its name to "Edesa Biotech Inc."
Key Financial Metrics and Transaction Terms
The filing does not provide historical revenue, profit, cash flow, or margin data for either entity. Key financial terms of the transaction include:
- Ownership Structure: Post-closing, Edesa shareholders and option holders are expected to own 90.0% of the combined company on a fully diluted basis, while existing Stellar shareholders will own 10.0%.
- Exchange Ratio Adjustments: The 90/10 split is subject to adjustment based on Stellar's working capital immediately prior to closing:
- If working capital is $3.5 million or more: 88.0% (Edesa) / 12.0% (Stellar).
- If working capital is less than $1.75 million: 92.0% (Edesa) / 8.0% (Stellar).
- Working Capital Condition: Closing requires Stellar's estimated working capital to be at least $1.5 million as of five business days before closing.
- Holdback Shares: A portion of shares will be held back to satisfy contractual cash payout rights of Stellar warrant holders within 30 days post-closing.
Material Changes and Governance
The transaction constitutes a change in control of the Registrant. The board of directors of the combined company will consist of seven members: four proposed by Edesa, one by Stellar, and two independent members. Additionally, Gregory T. Baxter, Ph.D., notified the company of his retirement as Executive Vice President of Corporate Development, effective March 22, 2019.
Guidance, Risks, and Contingencies
The transaction is subject to several material conditions and risks:
- Closing Conditions: Approval by Stellar shareholders, Nasdaq listing approval, and satisfaction of the $1.5 million working capital threshold.
- Termination Rights: The agreement may be terminated by June 28, 2019, if conditions are not met. Edesa may terminate if shareholder approval is not obtained by June 26, 2019, or if Stellar's working capital falls below $1.5 million.
- Termination Fees:
- Up to $250,000 in legal fees may be reimbursable to either party depending on the cause of termination.
- A $1,000,000 termination fee is payable by Stellar to Edesa if Stellar enters into a Superior Offer prior to shareholder approval.
- A $1,000,000 fee (less legal fees) is payable to Edesa if Stellar consummates an acquisition with a prior inquirer or shareholder within six months of termination.
- Regulatory Status: The issuance of shares to Edesa shareholders is exempt from registration under Regulation S as an offshore transaction to non-U.S. persons.
Investor Verification Checklist
- Verify the outcome of the Stellar shareholder vote required for transaction approval.
- Confirm Stellar's working capital position five business days prior to the anticipated closing date to determine the final exchange ratio.
- Review the definitive proxy statement for details on director interests and potential conflicts.
- Monitor Nasdaq's decision regarding the listing application for the combined entity.
- Check for any Superior Offers or acquisition inquiries that could trigger termination fees or alter the transaction timeline.